Covered recipient · General Payments record
ARNOLD L SILVA
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$103,928.07
174 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,801.00 | 15 |
| Compensation for serving as faculty or as a speaker for a medical education program | $26,157.00 | 9 |
| Consulting Fee | $20,888.50 | 8 |
| Travel and Lodging | $15,667.21 | 56 |
| Food and Beverage | $6,414.36 | 86 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Travere Therapeutics, Inc. | $33,471.29 | 72 |
| Bayer Healthcare Pharmaceuticals Inc. | $29,251.55 | 35 |
| Apellis Pharmaceuticals, Inc. | $20,527.16 | 21 |
| Lilly USA, LLC | $7,267.50 | 6 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $6,991.98 | 9 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,980.63 | 5 |
| AstraZeneca Pharmaceuticals LP | $2,035.24 | 9 |
| Calliditas Therapeutics US Inc. | $534.57 | 5 |
| Novartis Pharmaceuticals Corporation | $517.81 | 5 |
| Otsuka America Pharmaceutical, Inc. | $309.16 | 5 |
| Ardelyx, Inc. | $23.50 | 1 |
| Novo Nordisk Inc | $17.68 | 1 |
Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ARNOLD L SILVA
NPI 1497790646 · CMS profile ID 158060
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
MERIDIAN, ID
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1497790646?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ARNOLD L SILVA, NPI 1497790646, CMS profile ID 158060. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497790646?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ARNOLD L SILVA, NPI 1497790646, CMS profile ID 158060. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497790646?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ARNOLD L SILVA, NPI 1497790646, CMS profile ID 158060, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1497790646?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
174 matching records · $103,928.07 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 174.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $123.88 | 08/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801252 | CMS |
| Apellis Pharmaceuticals, Inc. | $2,000.00 | 08/19/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253189846 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $48.50 | 08/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801351 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $161.81 | 08/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801356 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $115.16 | 08/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801364 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $275.38 | 08/17/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801372 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $18.00 | 08/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801312 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $25.00 | 08/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801316 | CMS |
| Otsuka America Pharmaceutical, Inc. | $21.23 | 08/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227495027 | CMS |
| Apellis Pharmaceuticals, Inc. | $24.48 | 08/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253189872 | CMS |
| Apellis Pharmaceuticals, Inc. | $24.48 | 08/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253189882 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $6,242.00 | 08/01/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801278 | CMS |
| AstraZeneca Pharmaceuticals LP | $95.18 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206272288 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $869.40 | 07/26/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801320 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $125.00 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801260 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $293.96 | 07/11/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801360 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $496.60 | 07/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801291 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $22.10 | 07/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801368 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $6,242.00 | 06/27/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801274 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $39.03 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801256 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $724.37 | 06/26/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801335 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $1,971.00 | 06/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801324 | CMS |
| Novartis Pharmaceuticals Corporation | $115.51 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200385264 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $1,971.00 | 06/23/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801332 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $219.24 | 06/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801270 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $10.55 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801267 | CMS |
| Calliditas Therapeutics US Inc. | $99.81 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235008119 | CMS |
| Apellis Pharmaceuticals, Inc. | $3,597.00 | 06/13/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253189876 | CMS |
| Apellis Pharmaceuticals, Inc. | $1,242.64 | 06/13/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253189878 | CMS |
| Apellis Pharmaceuticals, Inc. | $21.48 | 06/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253189880 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $6,242.00 | 06/13/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801308 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $526.61 | 06/13/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801328 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $37.54 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801287 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $108.17 | 06/11/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801300 | CMS |
| Apellis Pharmaceuticals, Inc. | $98.59 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253189842 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $985.50 | 06/04/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801283 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $216.92 | 05/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801304 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $47.59 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801263 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,140.00 | 05/22/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222748540 | CMS |
| Calliditas Therapeutics US Inc. | $105.10 | 05/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235008117 | CMS |
| Lilly USA, LLC | $1,140.00 | 05/16/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186476509 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $457.97 | 05/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225801296 | CMS |
| Travere Therapeutics, Inc. | $2,500.00 | 04/25/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244413724 | CMS |
| Travere Therapeutics, Inc. | $17.24 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244396828 | CMS |
| Travere Therapeutics, Inc. | $28.00 | 04/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244413612 | CMS |
| Travere Therapeutics, Inc. | $41.80 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244413630 | CMS |
| Travere Therapeutics, Inc. | $82.09 | 04/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244413648 | CMS |
| Calliditas Therapeutics US Inc. | $102.06 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235008115 | CMS |
| Novo Nordisk Inc | $17.68 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188423125 | CMS |
| Lilly USA, LLC | $1,140.00 | 04/04/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186522191 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $347,489.14 | 47 |
| PY2024 | Principal investigator | $215,310.81 | 34 |
| PY2023 | Principal investigator | $169,341.45 | 40 |
| PY2022 | Principal investigator | $353,709.27 | 147 |
| PY2021 | Principal investigator | $355,162.16 | 389 |
| PY2020 | Principal investigator | $427,309.73 | 102 |
| PY2019 | Recipient | $1,528.89 | 9 |
| PY2019 | Principal investigator | $585,853.40 | 295 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
47 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 12/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension PLLC-Nampa | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220659098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 12/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension PLLC-Nampa | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220659100 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 12/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension PLLC-Nampa | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220659102 |
| Principal investigator 1 | ABBVIE INC. | $19,581.00 | 12/04/2025 | Non-covered Recipient Entity CARE INSTITUTE LLC | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | No dispute reported | 06/30/2026 | 1202528282 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.88 | 12/01/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension PLLC-Nampa | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220659096 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,124.00 | 11/24/2025 | Non-covered Recipient Entity ST LUKES CLINIC KIDNEY AND HYPERTENSION | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | No dispute reported | 06/30/2026 | 1190308258 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $10,800.00 | 11/05/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244186171 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $31,899.89 | 09/26/2025 | Non-covered Recipient Entity BOISE KIDNEY AND HYPERTENSION | A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy | No dispute reported | 06/30/2026 | 1214124054 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,800.00 | 09/24/2025 | Non-covered Recipient Entity CARE INSTITUTE LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223285858 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 09/24/2025 | Non-covered Recipient Entity CARE INSTITUTE LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223285860 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $2,047.00 | 09/24/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184148 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $250.00 | 09/09/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244184143 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,500.00 | 09/02/2025 | Non-covered Recipient Entity CARE INSTITUTE LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223284739 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $602.00 | 09/01/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244183919 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $500.00 | 09/01/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244184152 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,250.00 | 08/18/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184121 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $860.00 | 08/18/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184125 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $500.00 | 08/18/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184128 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $500.00 | 08/18/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184133 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $250.00 | 08/18/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184138 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,750.00 | 08/13/2025 | Non-covered Recipient Entity FRENOVA LLC | TAK-079-1006A STUDY OF MEZAGITAMAB IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY RECEIVING STABLE BACKGROUND THERAPY | No dispute reported | 06/30/2026 | 1223284125 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $152.55 | 08/13/2025 | Non-covered Recipient Entity FRENOVA LLC | TAK-079-1006A STUDY OF MEZAGITAMAB IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY RECEIVING STABLE BACKGROUND THERAPY | No dispute reported | 06/30/2026 | 1223284127 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $2,824.00 | 08/08/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244184103 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $515.00 | 08/08/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244184108 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,800.00 | 08/08/2025 | Non-covered Recipient Entity Care Cardio Renal Institute | DUPLEX study in FSGS | No dispute reported | 06/30/2026 | 1244184115 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 08/01/2025 | Non-covered Recipient Entity Boise Kidney and Hypertension Institute - Boise - Frenova | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215520359 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,200.00 | 08/01/2025 | Non-covered Recipient Entity Boise Kidney and Hypertension Institute - Boise - Frenova | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215520362 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,500.00 | 07/25/2025 | Non-covered Recipient Entity Boise Kidney and Hypertension Institute - Boise - Frenova | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215520356 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $6,515.60 | 07/07/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | Spartacus | No dispute reported | 06/30/2026 | 1244187161 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $32,759.23 | 03/27/2025 | Non-covered Recipient Entity FRENOVA RENAL RESEARCH | Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | No dispute reported | 06/30/2026 | 1185540221 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 03/24/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184845 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 03/24/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184850 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 03/24/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184855 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 03/24/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184861 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,472.53 | 03/05/2025 | Non-covered Recipient Entity FRENOVA LLC | TAK-079-1006A STUDY OF MEZAGITAMAB IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY RECEIVING STABLE BACKGROUND THERAPY | No dispute reported | 06/30/2026 | 1223276053 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,027.00 | 02/26/2025 | Non-covered Recipient Entity FRENOVA RENAL RESEARCH | A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease | No dispute reported | 06/30/2026 | 1185540219 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $164,065.31 | 01/28/2025 | Non-covered Recipient Entity BOISE KIDNEY AND HYPERTENSION | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) | No dispute reported | 06/30/2026 | 1214124926 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 01/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184815 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 01/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184819 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 01/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184824 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 01/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184827 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,499.00 | 01/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184832 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $512.00 | 01/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184836 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 01/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244184841 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 01/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244185047 |
| Principal investigator 1 | Travere Therapeutics, Inc. | $1,674.00 | 01/17/2025 | Non-covered Recipient Entity Boise Kidney And Hypertension | PROTECT Study in IgA Nephropathy | No dispute reported | 06/30/2026 | 1244185050 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $905.85 | 01/08/2025 | Non-covered Recipient Entity ST LUKES CLINIC KIDNEY AND HYPERTENSION | TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal | No dispute reported | 06/30/2026 | 1185540223 |